Selenium has been recognized as an essential element of human nutrition. Various forms of selenium, such as selenite, selenate, selenocysteine and selenomethionine, can be utilized as nutritional sources. [1] [2] [3] [4] Since selenomethionine is more effective and less toxic than inorganic selenium, synthetic selenomethionine or its enriched food sources are appropriate supplemental forms of selenium. David et al. 5) reported that some formula contained racemic selenomethionine. McAdam and Levander 6) showed little difference in the acute toxicity and nutritional bioavailability between D-and L-selenomethionine in rats and suggested that D-selenomethionine might be converted into the L-enantiomer. L-Selenomethionine is transformed to L-selenohomocysteine, similarly to the de-methylation pathway for L-methionine to Lhomocysteine. Then, L-selenohomocysteine is re-methylated to reform L-selenomethionine, or condensed with L-serine to form L-selenocystathionine, which is transformed to L-selenocysteine. However, little information is available on the metabolic fate of D-selenomethionine, especially conversion of D-selenomethionine into the L-enantiomer.
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In our previous study, the use of stable isotope labeled D-methionine and the stereoselective gas chromatographymass spectrometry-selected ion monitoring (GC-MS-SIM) method 7) proved to be a powerful methodology for examining the pharmacokinetic behavior of exogenously administered D-methionine and for studying the conversion of D-methionine into the L-enantiomer. We have shown that almost all Dmethionine exogenously administered were converted into the L-enantiomer in rats. 8) We have initiated studies to characterize the pharmacokinetic behavior of selenomethionine enantiomers by the stable isotope methodology. Successful application of the methodology to the metabolic investigation is dependent upon the availability of compounds labeled at predesigned positions. The present paper describes the preparation of optically pure D-and L-selenomethionine double-labeled with three deuteriums and 82 Se.
Results and Discussion
Convenient synthetic routes to selenomethionine labeled on selenium [9] [10] [11] or methyl group 12) have been published, but the synthesis of deuterium and 82 Se double-labeled selenomethionine has not been reported. With few exceptions, the synthesis of Se-labeled selenomethionine had been achieved by treating 2-amino-4-bromobutanoic acid with a labeled lithium methaneselenolate.
The synthetic route to D-and L-[ 2 H 3 , 82 Se]selenomethionine is illustrated in Chart 1. 2-Amino-4-bromobutanoic acid, a key intermediate in this synthesis, was obtained by either ring opening of 2-amino-4-butyrolactone (homoserine lactone) with HBr 13) or bromination of 2-amino-4-hydroxybutanoic acid (homoserine) with HBr in AcOH. 14) We have synthesized (R)-2-amino-4-hydroxybutanoic acid (2a) Se]selenomethionine were determined by HPLC with a chiral stationary column (Crownpak CR) eluted with 0.06% HClO 4 . Under these conditions, HPLC analysis of DLselenomethionine provided baseline separation at the retention time of 11.2 min (D-form) and 19.8 min (L-form) as shown in Fig. 1 . Both enantiomers were found to be Ͼ99% (ee). Figure 2 shows the chemical ionization mass spectra for N-isobutyloxycarbonyl ethyl ester derivatives of non-labeled selenomethionine, D ϩ clusters for the derivative of non-labeled selenomethionine appeared in the range of m/z 320 to 330, which corresponded to the isotopic isomer with natural abundances of C, H, O, N and Se isotopes. The relative intensities of the ion clusters were close to the theoretical values. The ion clusters derived from selenium isotopomers was disappeared on the mass spectrum for the derivatives of D-and L-[ 2 H 3 , 82 Se]selenomethionine. The mass peak at m/z 331 of [ 2 H 3 , 82 Se]selenomethionine did not overlap with the m/z peaks known from non-labeled selenomethionine.
The present procedure is a simple but effective for the synthesis of optically active selenomethionine double-labeled with deuterium and 82 Se. The stable isotope labeled selenomethionine should be useful for pharmacokinetic study.
Experimental
Materials and Methods DL-Selenomethionine, 45% HBr in acetic acid and isobutyl chloroformate were purchased from Wako Pure Chemicals (Osaka, Japan). (R)-2-Amino-4-butyrolactone hydrochloride and (S)-2-amino-4-bromobutyric acid hydrobromide were purchased from Aldrich (Milwaukee, U.S.A.). [ 2 H 3 ]Methyl iodide (Ͼ99.5% atom 2 H) was purchased from ISOTEC (Tokyo, Japan). 82 Se metal powder (Ͼ99.72% enriched) was purchased from Eurisotop (Gif-Sur-Yvette, France). All other chemicals and solvents were of analytical-reagent grade and were used without further purification. 1 H-NMR (400 MHz) and 13 C-NMR spectra (100 MHz) were recorded on a Bruker (Rheinstetten, Germany) DPX400 spectrometer. The samples were dissolved in deuterium oxide (0. C-NMR. J-Values were given in Hz. IR spectra were recorded on a Jasco (Tokyo, Japan) FT/IR-620 spectrometer. Optical rotations were measured on a Jasco P-1030 polarimeter. Mass spectra were obtained on a Micromass (Manchester, U.K.) Q-Tof Ultra mass spectrometer by electrospray ionization. Gas Chromatography-mass spectrometry (GC-MS) analysis was conducted on a Perkin-Elmer GC-MS system (GC AutoSystem XL with TurboMass Gold mass spectrometer, Norwalk, CT, U.S.A.). A methylsilicone bonded phase fused-silica capillary column Inertcep-1MS (15 mϫ 0.25 mm i.d.) with a 0.25 mm film thickness (GL Science, Tokyo, Japan) was connected directly to the ion source. The initial column temperature was set at 120°C. After the sample injection, it was maintained for 2 min and was increased at 40°C/min to 250°C. The temperature of the injector was 280°C. The mass spectrometer was operated in chemical ionization mode with isobutane as the reagent gas.
HPLC was performed on a Jasco PU-980 instrument equipped with a UV detector operated at 200 nm, a 3-line degasser and a Rheodyne injector with a 20-ml loop. Separation was carried out on a Crownpak CR column (150ϫ 4 mm i.d., Daicel Chemical, Tokyo, Japan) coupled with a guard column containing the same stationary phase (10ϫ4 mm i.d.) using 0.06% HClO 4 as mobile phase. The column temperature and flow rate were optimized to 25°C and 0.3 ml/min, respectively.
(R)-2-Amino-4-bromobutanoic Acid 2a: A solution of (R)-2-amino-4-butyrolactone hydrochloride 1a (306 mg, 2.2 mmol) in 45% HBr in acetic acid (10 ml) was refluxed for 5 h. The reaction mixture was allowed to stand for 12 h at room temperature to precipitate a colorless solid. The precipitate was collected and washed with diethyl ether. Recrystalization of the product 
